Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
acrv · stock forecast · 10 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$30.00
Consensus
$21.83
+1448.2% upside
Low
$17.00
Median: $20 · Last Close: $1.41
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.34 | ↓ 5.00% |
1-day model range: $1.31–$1.37. Peak: $1.37 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -40.7% |
| 2028 | — | -52.7% |
| 2029 | — | -57.6% |
| 2030 | — | -59.7% |
| 2031 | — | -60.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ACRV · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-01-09 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-11-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-14 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-05-16 | Jones Trading | Downgrade ↓ | Buy→Hold |
| 2025-05-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-03-28 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-26 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-03-26 | Citizens Capital Markets | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Acrivon Therapeutics, Inc. Common Stock (ACRV) stock. Of the recent 32 rating actions, 1 were upgrades and 2 were downgrades. 10 analysts currently cover ACRV.
Analyst Recommendation Trends
ACRV analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 93.0% YoY
Revenue Next Year
$0M
↓ 88.9% YoY
EPS This Year
$-2.07
EPS Next Year
$-1.95
↓ 5.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast ACRV EPS of $-2.07 for the current fiscal year, based on estimates from 6 analysts. The ACRV revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ACRV stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ACRV price target is $21.83 (+1448.2% upside), with an analyst consensus of Buy.
The ACRV short-term stock prediction for tomorrow is $1.34 (-5.00%). The ACRV stock prediction for 2030 projects a range of $1–$1.
Acrivon Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker ACRV. The ACRV stock outlook for 2027 is broadly positive, supported by a Buy consensus among 90% of covering analysts.
Frequently asked questions
ACRV forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month ACRV price target is $21.83, with a high forecast of $30.00 and a low of $17.00. The median price target is shown in the chart above when available. This implies +1448.2% potential upside from the current price of $1.41.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.